168 related articles for article (PubMed ID: 8271061)
21. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine.
Bergström M; Eriksson B; Oberg K; Sundin A; Ahlström H; Lindner KJ; Bjurling P; Långström B
J Nucl Med; 1996 Jan; 37(1):32-7. PubMed ID: 8543997
[TBL] [Abstract][Full Text] [Related]
22. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
23. Current imaging and possible therapeutic management of glucagonoma tumors: a case report.
Johnson DS; Coel MN; Bornemann M
Clin Nucl Med; 2000 Feb; 25(2):120-2. PubMed ID: 10656647
[TBL] [Abstract][Full Text] [Related]
24. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors.
Trautmann ME; Neuhaus C; Lenze H; Benning R; Benning M; Dennler HJ; Bruns C; Joseph K; Arnold R
Horm Metab Res Suppl; 1993; 27():24-7. PubMed ID: 8392487
[No Abstract] [Full Text] [Related]
25. [111IN-octreotide and 123I-MIBG scintigraphy in the diagnosis of small intestinal carcinoid tumors--results of a comparative investigation].
Dresel S; Tatsch K; Zachoval R; Hahn K
Nuklearmedizin; 1996 Apr; 35(2):53-8. PubMed ID: 8721576
[TBL] [Abstract][Full Text] [Related]
26. [Gammagraphy of somatostatin receptors in an ACTH secreting thymic carcinoid].
Banzo J; Razola P; Prats E; Freile E; Benito JL; García López F; García Tirado J; Abós MD
Rev Esp Med Nucl; 1999; 18(2):99-103. PubMed ID: 10352322
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin analogue scintigraphy in carcinoid tumours.
Kwekkeboom DJ; Krenning EP; Bakker WH; Oei HY; Kooij PP; Lamberts SW
Eur J Nucl Med; 1993 Apr; 20(4):283-92. PubMed ID: 8491220
[TBL] [Abstract][Full Text] [Related]
28. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
Cho KJ; Vinik AI
Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
[TBL] [Abstract][Full Text] [Related]
29. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Dörr U; Räth U; Sautter-Bihl ML; Guzman G; Bach D; Adrian HJ; Bihl H
Eur J Nucl Med; 1993 May; 20(5):431-3. PubMed ID: 8100192
[TBL] [Abstract][Full Text] [Related]
30. Intraoperative localization of gut endocrine tumors with radiolabeled somatostatin analogs and a gamma-detecting probe.
Benevento A; Dominioni L; Carcano G; Dionigi R
Semin Surg Oncol; 1998 Dec; 15(4):239-44. PubMed ID: 9829380
[TBL] [Abstract][Full Text] [Related]
31. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
[TBL] [Abstract][Full Text] [Related]
32. [Receptor scintigraphy in endocrine gastrointestinal and pancreatic tumors].
Joseph K; Stapp J; Reinecke J; Höffken H; Benning R; Neuhaus C; Trautmann ME; Schwerk WB; Arnold R
Dtsch Med Wochenschr; 1992 Jun; 117(26):1025-8. PubMed ID: 1352234
[No Abstract] [Full Text] [Related]
33. [A new diagnostic method: somatostatin receptor scintigraphy of neuroendocrine tumors].
Westlin JE; Janson ET; Ahlström H; Ohrvall U; Arnberg H; Nilsson S; Akerström G; Oberg K
Lakartidningen; 1992 Dec; 89(50):4377-9. PubMed ID: 1469974
[No Abstract] [Full Text] [Related]
34. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
Moattari AR; Deftos LJ; Vinik AI
J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
[TBL] [Abstract][Full Text] [Related]
35. Scintiscans and carcinoid tumors.
Carnaille B; Nocaudie M; Pattou F; Huglo D; Deveaux M; Marchandise X; Proye C
Surgery; 1994 Dec; 116(6):1118-21; discussion 1121-2. PubMed ID: 7985096
[TBL] [Abstract][Full Text] [Related]
36. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
Nauck C; Ivancević V; Emrich D; Creutzfeldt W
Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
[TBL] [Abstract][Full Text] [Related]
37. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
Virgolini I; Raderer M; Kurtaran A; Angelberger P; Banyai S; Yang Q; Li S; Banyai M; Pidlich J; Niederle B; Scheithauer W; Valent P
N Engl J Med; 1994 Oct; 331(17):1116-21. PubMed ID: 7935635
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
[TBL] [Abstract][Full Text] [Related]
39. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
[TBL] [Abstract][Full Text] [Related]
40. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.
Krenning EP; Bakker WH; Breeman WA; Koper JW; Kooij PP; Ausema L; Lameris JS; Reubi JC; Lamberts SW
Lancet; 1989 Feb; 1(8632):242-4. PubMed ID: 2563413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
